# C4 Therapeutics (stock symbol: CCCC) Logo in transparent PNG and SVG formats

## C4 Therapeutics Logo large

### C4 Therapeutics Logo large Download PNG (41.78 KB)

![C4 Therapeutics Logo large Download PNG (41.78 KB)](/img/orig/CCCC_BIG-9f545445.png)

### C4 Therapeutics Logo large Download SVG (11.58 KB)

![C4 Therapeutics Logo large Download SVG (11.58 KB)](/img/orig/CCCC_BIG-4eba309f.svg)

## C4 Therapeutics Logo icon format

### C4 Therapeutics Logo icon format Download PNG (85.99 KB)

![C4 Therapeutics Logo icon format Download PNG (85.99 KB)](/img/orig/CCCC-07069689.png)

### C4 Therapeutics Logo icon format Download SVG (3.12 KB)

![C4 Therapeutics Logo icon format Download SVG (3.12 KB)](/img/orig/CCCC-7aa64a64.svg)

## C4 Therapeutics Logo large for dark backgrounds

### C4 Therapeutics Logo large for dark backgrounds Download PNG (26.39 KB)

![C4 Therapeutics Logo large for dark backgrounds Download PNG (26.39 KB)](/img/orig/CCCC_BIG.D-edf54c0c.png)

### C4 Therapeutics Logo large for dark backgrounds Download SVG (10.54 KB)

![C4 Therapeutics Logo large for dark backgrounds Download SVG (10.54 KB)](/img/orig/CCCC_BIG.D-876ed370.svg)

## C4 Therapeutics Logo icon format for dark backgrounds

### C4 Therapeutics Logo icon format for dark backgrounds Download PNG (51.09 KB)

![C4 Therapeutics Logo icon format for dark backgrounds Download PNG (51.09 KB)](/img/orig/CCCC.D-fcb274ff.png)

### C4 Therapeutics Logo icon format for dark backgrounds Download SVG (3.07 KB)

![C4 Therapeutics Logo icon format for dark backgrounds Download SVG (3.07 KB)](/img/orig/CCCC.D-31d95960.svg)

## About C4 Therapeutics

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

1. Website domain: c4therapeutics.com
2. Employees: 121
3. Marketcap: $0.14 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
